Related Experiment Video
Updated: May 14, 2026
06:40
Cost-Efficient Transcriptomic-Based Drug Screening
Published on: February 23, 2024
Summary
Biotech therapies are expensive, costing thousands annually. Manufacturers must proactively demonstrate product value to health plans and employers to avoid externally imposed pricing.
Area of Science:
- Biotechnology
- Health Economics
- Pharmaceutical Policy
Background:
- High-cost biologic therapies present significant financial challenges for healthcare systems.
- Health plans and employers are actively seeking strategies to manage the increasing expenditure on novel biotech treatments.
Purpose of the Study:
- To highlight the critical need for biotechnology manufacturers to establish and communicate the value proposition of their high-cost therapies.
- To underscore the importance of proactive value demonstration in the face of potential external price definition by payers.
Main Methods:
- Analysis of current healthcare financing strategies for advanced therapies.
- Review of manufacturer-payer communication dynamics regarding drug pricing and value.
Main Results:
- Biotech therapies can cost "five and six figures per patient per year," necessitating strategic financial planning.
- Manufacturers face a critical window to define and communicate their product's value before payers do.
Conclusions:
- Proactive value communication by biotechnology firms is essential for appropriate reimbursement and market access.
- Failure to define value may lead to externally imposed pricing, potentially impacting manufacturer revenue and patient access.
More Related Videos
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
03:00Next-generation Sequencing
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...